Displaying 8 (all) recruiting clinical trials.
-
TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving ...Phase
Interventional
-
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1 ER Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)
This study wants to see if giving extra chemotherapy (adjuvant chemotherapy (ACT) to ovarian function suppression plus endocrine therapy) helps premenopausal women with early-stage breast ...
Phase
Interventional
-
Phase 3 Randomized Open-label Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
This is a Phase 3 trial testing whether the study medicine sacituzumab tirumotecan (an antibody-drug conjugate, also known as sac-TMT, or MK-2870), when given in ...
Phase
Interventional
-
A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
This is a Phase 3 study testing whether the study medicine MK-2870 is safer and more effective compared to the doctor's choice of other ...
Phase
Interventional
-
A Phase III randomized multi-site open-label trial of BNT323/DB-1303 versus investigator s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer (GOG 3105)
This is a Phase III study that is testing how well BNT323 works compared to a single chemotherapy drug chosen by the doctor. BNT323 is ...
Phase
Interventional
-
A Phase 3 Randomized Open-label Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
This is a Phase 3 randomized (split into groups by chance) study designed to compare how well and how safely sacituzumab tirumotecan, with or without ...
Phase
Interventional
-
A Phase 3 Randomized Open-label Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent Recurrent or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1
This is a Phase 3 study testing a new experimental drug called sacituzumab tirumotecan (sac-TMT, also known as MK-2870) to see if it can help ...
Phase
Interventional
-
FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
This is a Phase 3 study testing a new medicine called LY4170156 (an investigational antibody-drug conjugate) targeting FRa for patients with advanced ovarian cancer whose ...
Phase
Interventional
